Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 10
1997 7
1998 26
1999 25
2000 30
2001 29
2002 31
2003 38
2004 72
2005 66
2006 63
2007 99
2008 71
2009 81
2010 143
2011 182
2012 208
2013 211
2014 284
2015 288
2016 333
2017 325
2018 298
2019 288
2020 369
2021 370
2022 340
2023 35
Text availability
Article attribute
Article type
Publication date

Search Results

3,792 results
Results by year
Filters applied: . Clear all
Page 1
Pregnancy and multiple sclerosis: an update.
Varytė G, Arlauskienė A, Ramašauskaitė D. Varytė G, et al. Curr Opin Obstet Gynecol. 2021 Oct 1;33(5):378-383. doi: 10.1097/GCO.0000000000000731. Curr Opin Obstet Gynecol. 2021. PMID: 34310364 Free PMC article. Review.
Natalizumab may also be continued until 34 weeks of pregnancy for patients requiring persisting treatment. Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine …
Natalizumab may also be continued until 34 weeks of pregnancy for patients requiring persisting treatment. Drugs with a known potential of t …
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP, Cohen JA. McGinley MP, et al. Lancet. 2021 Sep 25;398(10306):1184-1194. doi: 10.1016/S0140-6736(21)00244-0. Epub 2021 Jun 24. Lancet. 2021. PMID: 34175020 Review.
The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod, siponimod, ozanimod, and ponesimod) have regulatory approval for multiple sclerosis. ...
The reduction in circulating lymphocytes presumably limits inflammatory cell migration into the CNS. Four S1PR modulators (fingolimod
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R, Alotaibi AA, Freedman MS. Roy R, et al. CNS Drugs. 2021 Apr;35(4):385-402. doi: 10.1007/s40263-021-00798-w. Epub 2021 Apr 2. CNS Drugs. 2021. PMID: 33797705 Review.
Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral disease-modifying therapy (DMT) used for the treatment of the relapsing forms of multiple sclerosi
Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-class sphingosine 1-phosphate (S1P) recepto
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J. Swallow E, et al. J Comp Eff Res. 2020 Mar;9(4):275-285. doi: 10.2217/cer-2019-0169. Epub 2020 Jan 17. J Comp Eff Res. 2020. PMID: 31948278 Free article. Clinical Trial.
Aim: Ozanimod and fingolimod are sphingosine 1-phosphate receptor-modulating therapies for relapsing multiple sclerosis. ...Conclusion: Ozanimod appears to have a favorable benefit-risk profile versus fingolimod....
Aim: Ozanimod and fingolimod are sphingosine 1-phosphate receptor-modulating therapies for relapsing multiple sclerosis. ...Conclusio …
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
Tsai HC, Han MH. Tsai HC, et al. Drugs. 2016 Jul;76(11):1067-79. doi: 10.1007/s40265-016-0603-2. Drugs. 2016. PMID: 27318702 Review.
However, the full extent of its involvement in the pathogenesis of autoimmune diseases is not well understood. FTY720 (fingolimod), a non-selective S1PR modulator, significantly decreased annualized relapse rates in relapsing-remitting multiple sclerosis (MS). ...
However, the full extent of its involvement in the pathogenesis of autoimmune diseases is not well understood. FTY720 (fingolimod), a …
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ, Cedeño RR, Casadevall MP, Ramió-Torrentà L. Bravo GÁ, et al. Cells. 2022 Jun 29;11(13):2058. doi: 10.3390/cells11132058. Cells. 2022. PMID: 35805142 Free PMC article. Review.
Modulation on S1P is an interesting target for the treatment of various autoimmune disorders. Improved understanding of the mechanism of action of fingolimod has allowed the development of the more selective second-generation S1PR modulators. Subtype 1 of the S1PR (S1PR1) …
Modulation on S1P is an interesting target for the treatment of various autoimmune disorders. Improved understanding of the mechanism of act …
Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism.
Xu Z, Ikuta T, Kawakami K, Kise R, Qian Y, Xia R, Sun MX, Zhang A, Guo C, Cai XH, Huang Z, Inoue A, He Y. Xu Z, et al. Nat Chem Biol. 2022 Mar;18(3):281-288. doi: 10.1038/s41589-021-00930-3. Epub 2021 Dec 22. Nat Chem Biol. 2022. PMID: 34937912
Here, we report the cryo-electron microscopy (cryo-EM) structures of G(i)-bound S1PR1 in complex with S1P, fingolimod-phosphate (FTY720-P) and siponimod (BAF312). In combination with functional assays and molecular dynamics (MD) studies, we reveal that the beta-arrestin-bi …
Here, we report the cryo-electron microscopy (cryo-EM) structures of G(i)-bound S1PR1 in complex with S1P, fingolimod-phosphate (FTY7 …
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.
Huwiler A, Zangemeister-Wittke U. Huwiler A, et al. Pharmacol Ther. 2018 May;185:34-49. doi: 10.1016/j.pharmthera.2017.11.001. Epub 2017 Nov 8. Pharmacol Ther. 2018. PMID: 29127024 Free article. Review.
The immunomodulatory drug fingolimod (FTY720, Gilenya(R)) was approved for oral treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good tolerability. ...As an alternative to fingolimod, novel S1PR modulators with a more selective …
The immunomodulatory drug fingolimod (FTY720, Gilenya(R)) was approved for oral treatment of relapsing-remitting multiple sclerosis, …
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J, Giovannoni G, Hunter SF. Chun J, et al. Drugs. 2021 Feb;81(2):207-231. doi: 10.1007/s40265-020-01431-8. Drugs. 2021. PMID: 33289881 Free PMC article. Review.
Previous and continuing investigation of the S1P pathway has led to the approval of three S1PR modulators, fingolimod, siponimod and ozanimod, as medicines for patients with multiple sclerosis (MS), as well as the identification of new S1PR modulators currently in clinical …
Previous and continuing investigation of the S1P pathway has led to the approval of three S1PR modulators, fingolimod, siponimod and …
Famous.
Kim MJ, Bhatti MT, Costello F. Kim MJ, et al. Surv Ophthalmol. 2016 Jul-Aug;61(4):512-9. doi: 10.1016/j.survophthal.2015.12.008. Epub 2015 Dec 29. Surv Ophthalmol. 2016. PMID: 26742785 Review.
A 62-year-old woman with multiple sclerosis experienced painless loss of vision in both eyes after starting fingolimod. Fundus examination revealed bilateral macular edema confirmed by optical coherence tomography. Fingolimod was discontinued, and a topical nonstero …
A 62-year-old woman with multiple sclerosis experienced painless loss of vision in both eyes after starting fingolimod. Fundus examin …
3,792 results